A follow-up of patients with idiopathic pulmonary fibrosis
https://doi.org/10.18093/0869-0189-2018-28-1-37-42
Abstract
The purpose of the study was to analyze results of 2-year follow-up of patients with idiopathic pulmonary fibrosis (IPF). Methods. Medical records of 83 patients admitted to the Pulmonology Department of the Territorial Teaching Hospital in 2013–2017 were analyzed retrospectively. Results. IPF patients were predominantly males (63.86%) over 50 years of age (90.37%). Two-year mortality rate was 26.5%. Died patients had significantly lower SpO2 and lung function (FVC and FEV1) and significantly higher serum C-reactive protein level at first admission compared to survived patients. Honeycomb lungs were seen at HRCT in 72.5% of died patients. In survived patients, SpO2 and 6-minute walk distance significantly decreased after 2 year of the follow-up. Proportion of patients with honeycomb lungs at HRCT increased from 20.8% to 75.0%. The diagnosis was revised in 8.4% of patients after 2 years of the follow-up. Conclusion. Patients with IPF should be referred to a multidisciplinary center as soon as possible in order to confirm the diagnosis, to be included in the register and to be regularly followed.
About the Authors
E. V. Bolotova
Kuban State Medical University, Healthcare Ministry of Russia; Federal Research Institute and S.V.Ochapovskiy Territorial Teaching Hospital No.1.
Russian Federation
Russian Federation
Elena V. Bolotova, Doctor of Medicine, Professor, Department of Pulmonology, Faculty of Postgraduate Physician Training.
ul. Sedina 4, Krasnodar, 350063.
L. V. Shul'zhenko
Kuban State Medical University, Healthcare Ministry of Russia; Federal Research Institute and S.V.Ochapovskiy Territorial Teaching Hospital No.1.
Russian Federation
Russian Federation
Larisa V. Shul'zhenko, Doctor of Medicine, Professor, Head of Department of Pulmonology, Faculty of Postgraduate Physician Training.
ul. Sedina 4, Krasnodar, 350063.
V. A. Porkhanov
Federal Research Institute and S.V.Ochapovskiy Territorial Teaching Hospital No.1; Kuban State Medical University, Healthcare Ministry of Russia.
Russian Federation
Russian Federation
Vladimir A. Porkhanov, Doctor of Medicine, Professor, Academician of Russian Academy of Science, Chief Medical Officer; Head of Department of Thoracic Surgery and Oncology.
ul. Pervogo maya 167, Krasnodar, 360086
I. N. Raybova
Kuban State Medical University, Healthcare Ministry of Russia.
Russian Federation
Russian Federation
Irina N. Raybova, Junior Physician, Department of Therapy No.1, Faculty of Postgraduate Physician Training.
ul. Sedina 4, Krasnodar, 350063.
N. I. Makrushina
Kuban State Medical University, Healthcare Ministry of Russia.
Russian Federation
Russian Federation
Nina I. Makrushina, Junior Physician, Department of Therapy No.1, Faculty of Postgraduate Physician Training.
ul. Sedina 4, Krasnodar, 350063.
References
1. Hobbs S., Lynch D. The idiopathic interstitial pneumonias: an update and review. Radiol. Clin. North Am. 2014; 52 (1): 105–120. DOI: 10.1016/j.rcl.2013.08.001.
2. Troy L., Corte T. Interstitial lung disease in 2015: where are we now? Aust. Fam. Physician. 2015; 44 (8): 546–552.
3. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI: 10.1164/rccm.201308-1483ST.
4. Cottin V., Crestani B., Valeyre D. et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur. Respir. Rev. 2014; 23 (132): 193–214. DOI: 10.1183/09059180.00001814.
5. Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21 (126): 355–361. DOI: 10.1183/09059180.00002512.
6. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237. DOI: 10.1186/s12916-015-0495-0.
7. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pul'monologiya. 2016; 26 (4): 399–419 (in Russian). DOI: 10.18093/0869-0189-2016-26-4-399-419.
8. Lee H.E., Myong J.P., Kim H.R. et al. Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int. J. Tuberc. Lung Dis. 2016; 20 (7): 978–984. DOI: 10.5588/ijtld.16.0003.
9. Harari S., Madotto F., Caminati A. et al. Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy. PLoS One. 2016; 11 (2): e0147072. DOI: 10.1371/journal.pone.0147072.
10. Hopkins R.B., Burke N., Fell C. et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur. Respir. J. 2016; 48 (1): 187–195. DOI: 10.1183/13993003.01504-2015.
11. Raghu G., Amatto V.C., Behr J. Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur. Respir. J. 2015; 46 (4): 1113–1130. DOI: 10.1183/13993003.02316-2014.
12. Gao F., Hobson A.R., Shang Z.M. et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. BMC Gastroenterol. 2015; 15: 26. DOI: 10.1186/s12876-015-0253-y.
13. Lynch J.P., Huynh R.H., Fishbein M.C. et al. Idiopathic pulmonary fibrosis: epidemiology, clinical features, prognosis, and management. Semin. Respir. Crit. Care Med. 2016; 37 (3): 331–357. DOI: 10.1055/s-0036-1582011.
14. Avdeev S.N. Idiopathic pulmonary fibrosis. Pul'monologiya. 2015; 25 (5): 600–612 (in Russian). DOI: 10.18093/0869-0189-2015-25-5-600-612.
15. Spagnolo P., Wells A.U., Collard H.R. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today. 2015; 20 (5): 514–524. DOI: 10.1016/j.drudis.2015.01.001.
16. Koroleva I.M Idiopathic pulmonary fibrosis. A radiologist’s reflection. Consilium Medicum. 2017; 19 (3): 8–13 (in Russian).
17. Golpe R., Pérez-de-Llano L.A., Méndez-Marote L., Veres-Racamonde A. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6-minute walk test in COPD patients. Respir. Care. 2013; 58 (8): 1329–1334. DOI: 10.4187/respcare.02290.
18. Hsieh M.H., Fang Y.F., Chung F.T. et al. Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. J. Thorac. Dis. 2017; 9 (9): 3168–3176. DOI: 10.21037/jtd.2017.08.53.
19. Bahmer T., Kirsten A.M., Waschki B. et al. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm. Med. 2017; 17 (1): 104. DOI: 10.1186/s12890-017-0444-0.
20. Schmidt S.L., Tayob N., Han M.K. et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014; 145 (3): 579–585. DOI: 10.1378/chest.13-0844.
21. Nishiyama O., Yamazaki R., Sano A. et al. Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis. Chron. Respir. Dis. 2016; 13 (1): 40–47. DOI: 10.1177/1479972315603714.
22. Doubková M., Švancara J., Svoboda M. et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin. Respir. J. 2017; Sep. 1. DOI: 10.1111/crj.12700
Review
For citations:
Bolotova E.V., Shul'zhenko L.V., Porkhanov V.A., Raybova I.N., Makrushina N.I. A follow-up of patients with idiopathic pulmonary fibrosis. PULMONOLOGIYA. 2018;28(1):37-42. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-1-37-42
Views:
938
Email this article 